TTK Healthcare Bonus Issue (20 Nov 2026)
TTK Healthcare Limited approves bonus issue of NCRPS to equity shareholders
TTK Healthcare · Diversified
Key highlights
- Issuance of 7.06 crore Non-Convertible Redeemable Preference Shares (NCRPS) of ₹100 each, totaling ₹706.52 crore
- Bonus ratio: 5 NCRPS for every 1 equity share held as on Record Date, with 9.5% annual dividend rate
- NCRPS tenure of 15 months from allotment, redeemable at par, listing proposed on BSE and NSE
Original filing
Board Meeting Outcome for Outcome Of Board Meeting
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Engineering Services
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other dividend / buyback / bonus filings this fortnight
- Dividend / buyback / bonusKama HoldingsKAMA Holdings approves ₹350 crore buyback of 14 lakh equity shares at ₹2,500 each
- Dividend / buyback / bonusJullundur Motor Agency (Delhi)Jullundur Motor Agency announces buyback of equity shares via tender offer
- Dividend / buyback / bonusDhampur Bio OrganicsDhampur Bio Organics Limited announces ₹50 crore equity shares buyback proposal
- Dividend / buyback / bonusAutomobile Corporation Of GoaAutomobile Corporation of Goa completes buyback of 1,44,639 equity shares
- Dividend / buyback / bonusGenus Power InfrastructuresGenus Power Infrastructures Limited completes buyback of equity shares worth ₹148.20 Crores
- Dividend / buyback / bonusAnlon Technology SolutionsAnlon Technology Solutions reports Q2 & H1 FY27 financial results and business updates
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.
